Uncategorized Archives - Page 13 of 87 - PsychedelicNewsWire (PNW)

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. "2021 was an exciting year for Cybin,” said Cybin CEO…

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

MondayJan 10, 2022 12:21 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…

MondayJan 10, 2022 12:04 pm

Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector

Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his…

MondayJan 10, 2022 10:26 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 12:00 pm

Clinical Psychologists Cautiously Evaluating Psychedelic-Backed Mental Health Treatment

A new survey has found that mental health professionals believe that psychedelic substances possess psychological benefits. This was despite concerns about the potential neurocognitive and psychiatric risks linked to using psychedelic treatment. Gabrielle Agin-Liebes, the author of the study, stated that while there was a lot of interest in the potential use of psychedelics in clinical care, there also existed a lot of negative attitudes toward psychedelic therapy. She explained that understanding the extent to which psychedelic treatments would be accepted in the healthcare system would help advance the clinical use of these drugs once they received approval for medical…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized